Free Trial

Bharat Biotech Applies For Fastrack For Candidate COVID-19 Vaccine

INDIA

Reports emerging that Bharat Biotech has applied for an emergency use authorisation (EUA) for its candidate COVID-19 vaccine 'Covaxin' from the Drugs Controller General of India (DCGI)

  • Vaccine being developed alongside the Indian Council of Medical Research (ICMR), and is the third potential vaccine to be submitted to the DCGI alongside that from Pfizer/BioNTech (approved by UK regulators earlier in December), and the Serum Institute of India.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.